INVESTOR PRESENTATION

Disclaimer

This Presentation and the accompanying slides (the “Presentation”), which have been prepared by Balaji Amines Limited (the “Company”),
have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe
for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company
makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness,
fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the
information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly
excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects
that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance
and are subject to known and unknown Risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties
include, but are not limited to the performance of the Indian economy and of the economies of various international markets, the
performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s
future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows,
the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity,
performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company
assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and
projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such
third party statements and projections.
Business Overview and Future Outlook
 Business Overview and Future Outlook
Balaji Amines Ltd., INDIA, an ISO 9001: 2015 certified company, specialised in manufacturing
Methylamines, Ethylamines, Derivatives of Specialty Chemicals. These have been the main
products, we also have facilities for the manufacture of derivatives, which are Key Raw
materials for various Pharma /Pesticide industries apart from user specific requirements.
BAL, one of the leading manufacturers of Aliphatic Amines in India was set up in the year
1988 to cater to the growing requirements of value based Specialty Chemicals. BAL
commenced manufacture of Methyl Amines in the year 1989 and subsequently added
facilities for manufacture of Ethyl Amines and other derivatives of Methyl Amines and Ethyl
Amines.
BAL has been consistently adding capacities and fine tuning processes to provide quality
products at lowest cost to the customers. World over, Amines Manufacturing technology is a
closely guarded process with only a few handful companies having access to such
technology.
Business Overview and Future Outlook
BAL for the first time in India tested on an indigenously developed technology and
developed it further over a period of time.

Today, BAL‘s products are accepted in international markets and have gained the distinct
export quality status, which makes it one of the few companies in India having the
potential to match the stringent international quality standards for which we have been
awarded ISO-9001: 2015 Certification apart from appreciation and continuous patronage
from global majors for our product range.

The plants are fully equipped with latest technology like Distributed Control
Systems(DCS) which facilitates the control of all operations from the control room on PC
in addition, BAL possesses an excellent R&D facilities Pilot plants and state of the art
laboratory facilities, which helps in conducting basic research and also to fine tune the
process.
Business Overview and Future Outlook
BALAJI SPECIALITY CHEMICALS PVT LTD
Balaji Speciality Chemicals Pvt Ltd (BSCPL) was incorporated in the year 2010 and
involved in various R&D activities in developing processes for some of the Specialty
chemicals. BSCPL became subsidiary of Balaji Amines Limited in 2018 by virtue of
Investment of 55% Stake in the equity. BSCPL has manufacturing facilities at MIDC,
Chincholi, Solapur for manufacture of unique products which are import substitutes and
first time being manufactured in India :
• Ethylenediamine (EDA), Capacity 22000 MT/Year
• Piperazine (Anhydrous), Capacity 3500 MT/Year
• Diethylenetriamine (DETA), Capacity 3500 MT/Year
• Aminoethylpiperazine (AEP), Capacity 1000 MT/Year
As per market data, last year India had Imported around 39000 MT EDA, 5000 MT
Piperazine and 4000 MT DETA. The Company’s installed capacity is 30000 TPA and
expected to start its production activities in FY 2019-20. The Company has got status of
“Mega Project” by the Government of Maharashtra.
RESEARCH & DEVELOPMENTS
BAL has in-house R&D centre recognised by the Department of Science and Technology,
Government of India.
BAL has been carrying out continuous Research and Development in the following areas
recently:
• Identification of new products and development of latest process technologies are
continuously worked on.
• Continuous improvement of processes and fine tuning of process parameters to
optimize utilization of energy, utilities & raw materials consumption and alternate
routes are being looked at.
• Backward and forward integration of products to improve value chain and better
utilization of all the resources.
RESEARCH & DEVELOPMENTS
• Adoption of advanced technologies in recovering waste heat, waste water has
resulted in minimizing the impact on environment and concentration of core principle
of Reduce, Reuse and Recycle of all the resources.
• For sustainable usage of natural resources, the Company has initiated various models
in reducing, reusing and recycling of various natural resources.
• Has initiated to use Renewable energy at every opportunity like, Wind mills, Solar
power and Waterless Cooling systems etc.,
Market Leadership

- Methyl Amines & Derivatives : Market Share of

> 60% in India

- Di-Methyl Amine Hydrochloride (DMA-HCL) :

nearly 60 to 70% of the global market share

- The only manufacturer in India of NMP, NEP,

Morpholine, 2-P, GBL, PVPK, DMF

- Most of our product selections are import

substitutes
 Usage
BAL caters to the industries which are considered to be important for growth of the
economy, it includes :

Active Pharmaceuticals Ingredients (APIs)

Agro –chemicals and pesticide formulations
Refineries
Water treatment chemicals
Rubber Chemicals
Electronics sector
Leather processing chemicals
Photographic chemicals
Dye stuff and paints industries
Animal Feed, Pharma Excipients

All above segments are growing at faster pace and this gives immense opportunity for
the company to leverage in these segments.
 Key Milestones
FY - 88
- Inception of Balaji Amines Limited to manufacturing Methyl Amines and Later added Ethyl Amines to the
range

FY - 91
- First Plant Commissioned for Manufacturing Aliphatic Amines at Tamalwadi, Solapur (Unit I)

FY - 92
- Developed its own in-house R&D center to manufacture few of the derivatives of Ethyl Amines, Methyl
Amines and Speciality chemicals
FY - 95
- Started Manufacturing Dimethyl Amine Hydrochloride (DMA-HCL) which is used for the diabetic drug like
Metformin, Tramadol etc.
- BAL got listed on The Bombay Stock Exchange through IPO at a Premium
FY - 2000
- BAL added derivatives of Ethyl Amines, Methyl Amines to its product range which included MMU, DMU,
DMAE, DEAE, CC, TMAHCL and DEAHCL
 Key Milestones
FY - 01
- BAL became ISO 9001 certified Company
FY - 03
- Second Expansion of DMAHCL Plant at Unit II
- Increased the Manufacturing capacity of Mythyl Amines
FY - 05
- Developed few more Speciality products like NMP, Morpholine at in-house R&D center

FY - 06
- Became first and sole manufacturer of GBL, NMP, Morpholine in India
- Started Balaji Foundation for social work
FY - 09
- Commissioned with an increased manufacturing capacity for the Unit III at MIDC, Chincholi, Solapur
- BAL got certification of “Recognized in-house R&D center by Ministry of Science & Technology
 Key Milestones
FY - 10
- Started PVP-K30 (Polyvinyl Pyrrolidone) plant
- Started Dimethyl Amino Ethanol (DMAE) plant
FY - 11
- Started GBL, NMP/2P

FY - 12

- Expanded Methylamines plant

FY - 13

- Started Dimethyl Formamide for the First time and Expanded Dimethyl Amine Hydrochloride

FY - 14

- Started Hotel Division “Balaji Sarovar Premiere”

 Key Milestones
FY - 18

- Allotment of 90 Acres of Land at MIDC, Chincholi and the Maharashtra state Government has accorded
“Mega Project” Status for this new Project
- new plant for manufacture of Morpholine and Acetonitrile is commissioned after successful trial runs and
ready to be operational
- BSCPL became Subsidiary of BAL which will start its production activities in 2019-20
Standalone Profit & Loss
(Rs. In Lakhs)
Sl. Particulars Quarter ended Nine months ended Year ended
No.
31.12.2018 30.09.2018 31.12.2017 31.12.2018 31.12.2017 31.03.2018

1 Total Income from Operations 24085.81 21787.11 21940.39 71989.10 62288.35 88104.73

2 Net Profit before Tax, Exceptional and/or

Extraordinary items 3550.41 3837.26 4498.83 12560.83 12585.71 16523.93

3 Net Profit for the period before tax after

Exceptional and/or Extraordinary items 3550.41 4193.25 4558.74 12916.82 12645.62 16583.84

4 Net Profit for the period after tax after

Exceptional and/or Extraordinary items 2627.39 3098.07 2808.66 9107.81 8000.50 11318.10

5
Total Comprehensive Income for the period 2627.39 3098.07 2808.66 9107.81 8000.50 11318.10
6 Equity Share Capital 648.02 648.02 648.02 648.02 648.02 648.02

7
Reserves (excluding Revaluation Reserve) 46058.33 46058.33 37078.55 46058.33 37078.55 37078.55
8 Earnings Per Share
1. Basic: 8.11 9.56 8.67 28.11 24.69 34.93
2. Diluted: 8.11 9.56 8.67 28.11 24.69 34.93
Key Financial Highlights
Net Sales (in Lacs)
1,00,000.00

90,000.00

80,000.00

70,000.00

60,000.00

50,000.00

86364.74
40,000.00

66753.42
61012.63 63492.35
30,000.00 60486.18
51179.6
44952.36
20,000.00
35709.56
26189.58
10,000.00

0.00
2009-10 2010-11 2011-12 2012-13 2013-14 2014-15 2015-16 2016-17 2017-18 2018-19

Sales (in Lacs)

Key Financial Highlights
PAT (in Lacs)
12,000.00

10,000.00

8,000.00

6,000.00
11318.1

8557.32
4,000.00

6127.06

2,000.00
3566.17 3352.27 3635.82
3118.35
2661.36
2064.95

0.00
2009-10 2010-11 2011-12 2012-13 2013-14 2014-15 2015-16 2016-17 2017-18 2018-19

PAT (in Lacs)

Key Financial Highlights

PBT (in Lacs)

18,000.00

16,000.00

14,000.00

12,000.00

10,000.00

8,000.00 16583.84

13048.45
6,000.00

9315.44
4,000.00

5274.07 5574.06
2,000.00 4297.78 4595.6 4564.31
3156.45

0.00
2009-10 2010-11 2011-12 2012-13 2013-14 2014-15 2015-16 2016-17 2017-18 2018-19

PBT (in Lacs)

Key Financial Highlights

EBIDTA (in Lacs)

25,000.00

20,000.00

15,000.00

10,000.00 19416.64

16039.13
13113.65
5,000.00 10574.69
9361.85
8350.03 8392.63
6479.7
4774.24

0.00
2009-10 2010-11 2011-12 2012-13 2013-14 2014-15 2015-16 2016-17 2017-18 2018-19

EBITDA (in Lacs)

Key Financial Highlights

ROCE (in %)
35.00

30.00

25.00

20.00

15.00 31.05
27.12 27.98
23.683 24.47
22.17 22.98
10.00 19.13 18.08

5.00

0.00
2009-10 2010-11 2011-12 2012-13 2013-14 2014-15 2015-16 2016-17 2017-18 2018-19

ROCE (in %)
Key Financial Highlights

ROE (in %)
30.00

25.00

20.00

15.00

24.39 24.23
22.68
10.00 21
18.67 19.09
18.08
16.58
15.3

5.00

0.00
2009-10 2010-11 2011-12 2012-13 2013-14 2014-15 2015-16 2016-17 2017-18 2018-19

ROE (in %)